Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -78.9%
Financial Fact:
Loss from operations: -34.93M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of $0.00, $0.03 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $21.4 million versus the consensus estimate of $11.97 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Premarket movers: Xenon sinks on trial pause, Netflix hit by downgrade
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
